‘Cicada’ COVID is gaining ground in reported infections, and its symptom profile is drawing fresh attention from clinicians and public health teams. Early cases point to a familiar pattern: the virus targets the upper respiratory tract, spreads efficiently in indoor air, and can still cause serious illness in people with underlying conditions or reduced immune response.

Doctors describe a cluster of leading signs: sore throat, nasal congestion, cough, headache, and pronounced fatigue. Many patients report fever and chills, driven by the body’s innate immune response and cytokine release, while some experience muscle aches and shortness of breath. Loss of smell and taste appears less common than in earlier waves, but it has not disappeared. Gastrointestinal symptoms, including nausea and diarrhea, are being recorded in a minority of cases, reflecting viral replication in mucosal tissues beyond the lungs.

Laboratories tracking the spike protein sequence classify Cicada within the broader family of Omicron‑lineage variants, which remain highly transmissible through respiratory droplets and aerosols. Polymerase chain reaction testing and rapid antigen tests still detect the infection, though sensitivity can vary over the course of viral load dynamics. Vaccination and recent boosters continue to reduce the risk of severe disease by priming adaptive immunity, and masks, ventilation, and isolation after a positive test remain the most reliable tools to slow the variant’s spread.